Rezolute, Inc. (RZLT) SEC Filings & Earnings Calls

Share dilution risk from authorized share increase

“The issuance in the future of additional authorized shares of common stock may have the effect of diluting the earnings or loss per share and book value per share, as well as the ownership and voting rights of the holders of our then-outstanding shares of common stock.” · word for word

Anti-takeover risk from authorized share increase

“An increase in the number of authorized but unissued shares of common stock may have a potential anti-takeover effect, as our ability to issue additional shares could be used to thwart persons, or otherwise dilute the stock ownership of stockholders, seeking to control our Company.” · word for word

One participant died due to cancer progression, considered non-responder; small sample size (n=16) increases statistical uncertainty

“The eighth participant in the first half of the study elected to pursue hospice care at home shortly after enrollment, where they died one week later due to cancer progression. The Company considers this participant as a non-responder” · word for word

Regulatory approval not guaranteed; FDA did not opine on approvability.

“Agency explicitly did not opine on the approvability of ersodetug for congenital HI.” · word for word

Clinical trial failure

“On December 11, 2025, we announced that the sunRIZE study did not meet its primary endpoint (hypoglycemia events by finger stick self-monitored blood glucose “SMBG”) or its key secondary endpoint (time in hypoglycemia by continuous glucose monitoring “CGM”) at the defined Week 24 evaluable window.” · word for word

Regulatory path uncertainty

“FDA encouraged us to submit comprehensive analysis datasets and summary outcomes for the Agency’s independent evaluation. Following that review, we believe that a determination may be made whether there is sufficient evidence to support the submission of a marketing application for sunRIZE or if additional information and/or clinical studies are required” · word for word

Cash runway / need for additional capital

“We incurred net losses of $77.6 million and $74.4 million for the fiscal years ended June 30, 2026 and 2025, respectively. As of June 30, 2026, we had cash and cash equivalents of $10.6 million and investments in marketable debt securities of $97.2 million”

Phase 3 sunRIZE study failure in congenital HI creates regulatory uncertainty; FDA review ongoing with no clear timeline.

“data from the Phase 3 sunRIZE study in congenital HI, which did not meet its primary endpoint, remains under review with the U.S. Food and Drug Administration” · word for word

Cash burn rate may require additional financing before potential approval; cash decreased ~36% year-over-year.

“Cash, cash equivalents and investments in marketable securities were $107.8 million as of June 30, 2026, compared with $167.9 million as of June 30, 2025.” · word for word

Clinical trial failure risk

“On December 11, 2025, we announced that the sunRIZE study did not meet its primary (hypoglycemia events) or key secondary (time in hypoglycemia) endpoints.” · word for word

Regulatory approval risk

“The FDA may reject the additional datasets we are preparing in support of the sunRIZE trial.” · word for word

Cash runway risk

“We expect to incur operating losses for the foreseeable future; therefore, we expect to continue efforts to raise additional capital to maintain our current operating plans over the next several years.” · word for word

Regulatory uncertainty: FDA acknowledged challenges but did not provide clear approval path; requires comprehensive data submission.

“FDA acknowledged the challenges... encouraged Rezolute to submit comprehensive analysis datasets and summary outcomes for the agency’s independent evaluation.” · word for word

Cash burn rate: $47.6M decrease in cash over 9 months; no revenue; reliance on capital markets.

“Cash decreased from $167.9M to $120.3M over 9 months.”

Single product dependency: ersodetug is the only late-stage asset; any setback would be material.

“All programs are based on ersodetug for hyperinsulinism.”

Clinical Trial Failure

“On December 11, 2025, we announced that the sunRIZE study did not meet its primary (hypoglycemia events) or key secondary (time in hypoglycemia) endpoints.” · word for word

Regulatory Uncertainty

“We will be meeting with the FDA prior to the end of calendar Q1 2026 under our Breakthrough Therapy Designation to further characterize these and other clinical outcomes to discuss the full sunRIZE dataset and next steps for this indication.” · word for word

Litigation Risk

“Following the release of the results of our sunRIZE trial our stock price suffered a decline. As a result, plaintiffs law firms have announced investigations into potential securities laws violations.” · word for word

Cash Runway Risk

“We expect to incur operating losses for the foreseeable future; therefore, we expect to continue efforts to raise additional capital to maintain our current operating plans over the next several years.” · word for word

Phase 3 sunRIZE trial failure for congenital HI; regulatory path uncertain.

“The study did not meet its primary or key secondary endpoints.” · word for word

Cash burn rate; $35M decrease in 6 months.

“Cash, cash equivalents and investments in marketable securities were $132.9 million as of December 31, 2025, compared with $167.9 million as of June 30, 2025.” · word for word

Reduction in force and severance costs impacting expenses.

“one-time severance benefits related to the December 2025 reduction in force” · word for word

No approved products or revenue

“We have not generated any meaningful revenues since our inception in March 2010.” · word for word

Dependence on clinical trial success

“We expect to incur operating losses for the foreseeable future; therefore, we expect to continue efforts to raise additional capital to maintain our current operating plans over the next several years.” · word for word

Need for additional financing

“We cannot assure you that we will secure such financing or that it will be adequate for the long-term execution of our business strategy.” · word for word

Clinical trial failure risk; cash burn rate may require future financing.

“Net loss increased; cash decreased by $15.7M in quarter; no revenue.”